MPM ASSET MANAGEMENT LLC - Q3 2022 holdings

$263 Million is the total value of MPM ASSET MANAGEMENT LLC's 9 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 10.0% .

 Value Shares↓ Weighting
 Entrada Therapeutics, Inc.$69,750,000
+29.4%
4,425,7840.0%26.57%
+16.8%
DYN  Dyne Therapeutics, Inc.$62,882,000
+84.9%
4,951,3030.0%23.95%
+66.9%
ITOS  iTeos Therapeutics, Inc.$52,174,000
-7.5%
2,738,7850.0%19.87%
-16.5%
RPTX  Repare Therapeutics, Inc.$27,203,000
-13.3%
2,242,6360.0%10.36%
-21.7%
HOWL  Werewolf Therapeutics, Inc.$19,322,000
+10.3%
4,284,1720.0%7.36%
-0.5%
AMYT  Amryt Pharma plc$18,468,000
-1.0%
2,668,8430.0%7.03%
-10.6%
TCRR  TCR2 Therapeutics, Inc.$7,292,000
-37.9%
4,050,8650.0%2.78%
-44.0%
HARP  Harpoon Therapeutics, Inc.$3,037,000
-49.2%
3,131,3880.0%1.16%
-54.2%
ONCR  Oncorus, Inc.$2,422,000
-32.5%
2,849,4640.0%0.92%
-39.1%
RYTM ExitRhythm Pharmaceuticals, Inc.$0-909,258
-100.0%
-1.59%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Chiasma, Inc.24Q2 202119.8%
Aratana Therapeutics, Inc.24Q1 201926.8%
Conatus Pharmaceuticals, Inc.23Q1 20199.7%
Rhythm Pharmaceuticals, Inc.19Q2 202269.9%
Harpoon Therapeutics, Inc.19Q3 202331.9%
Syndax Pharmaceuticals, Inc.19Q3 202014.5%
Radius Health, Inc.17Q2 201876.4%
TCR2 Therapeutics, Inc.17Q1 202329.1%
Proteon Therapeutics, Inc.17Q4 20183.0%
EpiZyme, Inc.15Q4 201635.9%

View MPM ASSET MANAGEMENT LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-14
13F-HR/A2023-09-07
13F-HR2023-08-14
42023-06-05
42023-05-24
13F-HR2023-05-12
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11

View MPM ASSET MANAGEMENT LLC's complete filings history.

Compare quarters

Export MPM ASSET MANAGEMENT LLC's holdings